Materials and methods for altering an immune response to exogenous and endogenous immunogens, including syngeneic and non-syngeneic cells, tissues or organs
원문보기
IPC분류정보
국가/구분
United States(US) Patent
등록
국제특허분류(IPC7판)
A61K-035/12
A61K-035/28
A61K-035/26
A61K-035/44
A61K-039/00
C12N-005/071
A61K-009/00
A61K-045/06
출원번호
US-0570320
(2012-08-09)
등록번호
US-9040092
(2015-05-26)
발명자
/ 주소
Edelman, Elazer R.
Nugent, Helen Marie
Methe, Heiko
출원인 / 주소
Massachusetts Institute of Technology
대리인 / 주소
K&L Gates LLP
인용정보
피인용 횟수 :
3인용 특허 :
48
초록▼
Disclosed herein are materials and methods for modulating an immunologically adverse response to an exogenous or endogenous immunogen, including a cell, tissue, or organ associated immunogen. An implantable material comprising cells, such as but not limited to endothelial cells, anchored or embedded
Disclosed herein are materials and methods for modulating an immunologically adverse response to an exogenous or endogenous immunogen, including a cell, tissue, or organ associated immunogen. An implantable material comprising cells, such as but not limited to endothelial cells, anchored or embedded in a biocompatible matrix can modulate an adverse immune or inflammatory reaction to exogenous or endogenous immunogens, including response to non-syngeneic or syngeneic cells, tissues or organs, exogenous immunogens or stimuli, as well as ameliorate an autoimmune condition. The implantable material can be provided prior to, coincident with, or subsequent to occurrence of the immune response or inflammatory reaction. The implantable material can induce immunological acceptance in a transplant patient, reduce graft rejection and reduce donor antigen immunogenicity.
대표청구항▼
1. A method of treating a recipient of a cell, tissue or organ from a donor, the method comprising the steps of: administering to the recipient one or more doses of a cell, tissue or organ from a syngeneic or non-syngeneic donor; andproviding to the recipient an implantable material comprising a bio
1. A method of treating a recipient of a cell, tissue or organ from a donor, the method comprising the steps of: administering to the recipient one or more doses of a cell, tissue or organ from a syngeneic or non-syngeneic donor; andproviding to the recipient an implantable material comprising a biocompatible matrix; and,endothelial cells anchored or embedded in a 3D matrix,wherein the providing step is prior to, coincident with, or subsequent to administration to said recipient of the one or more doses of a cell, tissue or organ from a syngeneic or non-syngeneic donor, andwherein said implantable material is delivered locally at a non-luminal site to the recipient in an amount sufficient to systemically modulate the recipient's humoral or cellular immune response to said donor cell, tissue or organ. 2. The method of claim 1, wherein said method modulates a recipient's humoral or cellular immune response to administration of a non-syngeneic donor cell, tissue or organ. 3. The method of claim 1, wherein modulation of the recipient's immune response results in reduced maturation of innate immune cells, wherein said innate immune cells are selected from the group consisting of NK cells, dendritic cells, monocytes, and macrophages. 4. The method of claim 3, wherein modulation of the recipient's immune response results in reduced expression by dendritic cells of HLA-DR, IL 12, Toll-like receptor or CD83; inhibits dendritic cell-induced lymphocyte proliferation; or inhibits proliferation, activation or differentiation of dendritic cells. 5. The method of claim 1, wherein the cells embedded in the matrix are autologous, allogeneic, xenogeneic or genetically-modified variants or any one of the foregoing. 6. A method of treating an individual exposed to an exogenous immunogen, the method comprising the steps of: identifying an individual exposed to or likely exposed to an exogenous immunogen; andadministering to the individual exposed to the exogenous immunogen an implantable material comprisinga biocompatible matrix; and,endothelial cells anchored or embedded in a 3D matrix,wherein the administering step is prior to, coincident with, or subsequent to the exogenous immunogen, andwherein said implantable material is administered locally at a non-luminal site to said individual exposed to the exogenous immunogen in an amount sufficient to systemically reduce the exposed individual's immune inflammatory reaction resulting from exposure to the exogenous immunogen. 7. The method of claim 6, wherein said exogenous immunogen is naturally occurring. 8. The method of claim 6, wherein said exogenous immunogen is selected from the group consisting of pharmaceutical agents, toxins, surgical implants, infectious agents and chemicals. 9. The method of claim 6, wherein the cells embedded in the matrix are autologous, allogeneic, xenogeneic or genetically-modified variants or any one of the foregoing. 10. The method of claim 1, wherein the cells embedded in the matrix are vascular endothelial cells. 11. The method of claim 6, wherein the cells embedded in the matrix are vascular endothelial cells. 12. The method of claim 1, wherein the cells embedded in the matrix are selected from the group consisting of: progenitor cells, stem cells, non-endothelial cells, and genetically-altered, -engineered or -modified cells. 13. The method of claim 6, wherein the cells embedded in the matrix are selected from the group consisting of: progenitor cells, stem cells, non-endothelial cells, and genetically-altered, -engineered or -modified cells.
연구과제 타임라인
LOADING...
LOADING...
LOADING...
LOADING...
LOADING...
이 특허에 인용된 특허 (48)
Iyer, Sriram S.; Kipshidze, Nicholas N.; Nikolaychik, Victor V., Apparatus and methods for preventing or treating failure of hemodialysis vascular access and other vascular grafts.
Barrera Denise (Oakdale MN) Langer Robert S. (Newton MA) Lansbury ; Jr. Peter T. (Brookline MA) Vacanti Joseph P. (Winchester MA), Biodegradable polymers for cell transplantation.
Vacanti Joseph P. ; Vacanti Charles A. ; Langer Robert S., Biodegradable synthetic polymeric fibrous matrix containing chondrocyte for in vivo production of a cartilaginous struct.
Edelman Elazer R. (Brookline MA) Adams David H. (Boston MA) Karnovsky Morris J. (Newton Centre MA), Extraluminal regulation of the growth and repair of tubular structures in vivo.
Edelman Elazer R. (Brookline MA) Adams David H. (Boston MA) Karnovsky Morris J. (Newton Centre MA), Extraluminal regulation of the growth and repair of tubular structures in vivo.
Edelman Elazer R. (Brookline MA) Adams David H. (Boston MA) Karnovsky Morris J. (Newton Centre MA), Extraluminal regulation of the growth and repair of tubular structures in vivo.
Vacanti Joseph P. (Winchester MA) Freeman Michael R. (Boston MA), Genitourinary cell-matrix structure for implantation into a human and a method of making.
Edelman Elazer R. ; Nathan Aruna ; Nugent Matthew A., Inhibition of vascular smooth muscle cell proliferation with implanted matrix containing vascular endothelial cells.
Yannas Ioannis V. (Newton Center MA) Burke John F. (Belmont MA) Orgill Dennis P. (Cambridge MA) Skrabut Eugene M. (Beverly MA), Method of promoting the regeneration of tissue at a wound.
Williams Stuart K. (Drexel Hill PA) Jarrell Bruce E. (Philadelphia PA), Method of treating a synthetic or naturally occuring surface with microvascular endothelial cells, and the treated surfa.
McKenzie, John R.; Zuk, Robert F.; Brisken, Axel F.; Corl, Paul D., Methods and kits for the inhibition of hyperplasia in vascular fistulas and grafts.
Silver Jerry (Lyndhurst) Smith George M. (Cleveland) Jacobberger James W. (Chesterland OH), Methods of reducing glial scar formation and promoting axon and blood vessel growth and/or regeneration through the use.
Ingber Donald E. ; Langer Robert S. ; Vacanti Joseph P., Seeding parenchymal cells into compression resistant porous scaffold after vascularizing in vivo.
※ AI-Helper는 부적절한 답변을 할 수 있습니다.